<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730067</url>
  </required_header>
  <id_info>
    <org_study_id>2008-002237-73</org_study_id>
    <nct_id>NCT00730067</nct_id>
  </id_info>
  <brief_title>Sildenafil for Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension</brief_title>
  <official_title>Sildenafil for COPD-associated Pulmonary Hypertension. A Randomized Double Blinded Placebo Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic obstructive pulmonary disease (COPD)can be complicated by an increased pressure in
      the pulmonary circulation. This worsens the prognosis, but so far it is unknown whether
      treatment of the increased pulmonary blood pressure betters the patients symptoms.

      In this study 32 patients with increased pulmonary blood pressure due to COPD will be
      randomized to 3 months treatment with placebo or sildenafil, which is known to lower the
      pulmonary blood pressure in other types of pulmonary hypertension.

      Our hypothesis is that treatment with sildenafil in these patients will improve the
      functional capacity measured by the distance walked in 6 minutes and life quality.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    As a single center, it was not possible to recruit enough patients with pulmonary hypertension
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 minute walk test</measure>
    <time_frame>at base line, after 2 hours and after 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>assessment of life quality</measure>
    <time_frame>At baseline and follow up after three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic pulmonary pressure</measure>
    <time_frame>At baseline and follow-up after three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of symptoms measured by use of short acting beta agonists</measure>
    <time_frame>At baseline and follow-up after three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of NT-proBNP and apelin</measure>
    <time_frame>At baseline and follow-up after three months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COPD</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>Sildenafil 50 mg three times daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A mean pulmonary arterial pressure of 25 mmHg measured by right heart catheterization.

          -  A diagnosis of COPD-associated pulmonary hypertension, implicating that no other
             potential cause of pulmonary hypertension is present.

          -  Stable COPD, defined by no subjective alterations of symptoms or use of short acting
             beta-antagonists for minimally six weeks. Any exacerbation resulting in admission to
             hospital or other contacts to a physician must have ceased for at least 6 weeks before
             entering the study.

          -  Age &gt; 18

          -  Informed written consent.

          -  Reliable anticonception for fertile women.

        Exclusion Criteria:

          -  Rheumatic disease limiting walking capacity.

          -  Exacerbation in COPD during the study.

          -  Age&gt;80 years

          -  FEV1 &lt; 25 % of predicted.

          -  Allergy towards contents of sildenafil or placebo tablets.

          -  Fall in blood pressure of &gt; 30 mmHg systolic or &gt;20 mmHg diastolic after intake of the
             first dose of trial medication.

          -  Fall in peripheral saturation of &gt; 5% after intake of the first dose of trial
             medication.

          -  Treatment with nitrous vasodilators or aminophyllamines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole Hilberg, MDSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Århus Sygehus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Erik Nielsen-Kudsk, MDSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skejby Sygehus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Skejby sygehus</name>
      <address>
        <city>Århus N</city>
        <zip>DK_8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pulmonary Diseases, Århus Sygehus</name>
      <address>
        <city>Århus</city>
        <zip>Dk-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Charlotte Andersen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Pulmonary hypertension</keyword>
  <keyword>Sildenafil</keyword>
  <keyword>NT-pro BNP</keyword>
  <keyword>apelin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

